Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRY001
MIFTS: 50

Trypanosomiasis

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Trypanosomiasis

About this section

MalaCards integrated aliases for Trypanosomiasis:

Name: Trypanosomiasis 12 54 44 15 71

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:10113
ICD9CM 34 086
MeSH 44 D014352
SNOMED-CT 67 266205000
ICD10 32 B57.2
UMLS 71 C0041227
Sources

Summaries for Trypanosomiasis

About this section
Disease Ontology : 12 A parasitic protozoa infectious disease that involves infection caused by parasitic protozoan of the genus Trypanosoma in animals and humans.

MalaCards based summary : Trypanosomiasis is related to sleeping sickness and chagas disease. An important gene associated with Trypanosomiasis is APOL1 (Apolipoprotein L1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Nifurtimox and Ornithine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Sources

Related Diseases for Trypanosomiasis

About this section

Diseases related to Trypanosomiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 833)
# Related Disease Score Top Affiliating Genes
1 sleeping sickness 33.1 ODC1 IL6 IL10 HPR HP APOL1
2 chagas disease 32.4 TNF ODC1 IL6 IL4 IL1B IL18
3 meningoencephalitis 31.4 TNF IL6 IL10 CXCL10 ALB
4 leishmaniasis 31.2 TNF TLR9 IL6 IL4 IL1B IL1A
5 babesiosis 30.9 IL10 HP ALB
6 filariasis 30.9 TNF TLR9 IL6 IL10 IFNG ALB
7 myocarditis 30.9 TNF IL6 IL4 IL1B IL18 IL10
8 encephalitis 30.8 TNF IL6 IL1B IL10 IDO1 CXCL10
9 disseminated intravascular coagulation 30.8 TNF IL6 IL10
10 acquired immunodeficiency syndrome 30.7 TNF IL6 IL1B IL10 IFNG ALB
11 congestive heart failure 30.7 TNF IL6 IL1B ALB
12 echinococcosis 30.7 TNF IL6 IL10 IFNG
13 schistosomiasis 30.7 TNF IL4 IL1A IL10 IFNG CCL2
14 toxoplasmosis 30.6 TNF TLR9 MYD88 IL6 IL4 IL1B
15 intracranial hypertension 30.6 TNF IL1B CXCL10
16 amebiasis 30.6 TNF IL4 IL1B IL10 CXCL8 ALB
17 lymphopenia 30.5 IL6 IL4 IL10 IFNG
18 diarrhea 30.5 TNF IL6 IL1B IL10 IFNG CXCL8
19 glomerulonephritis 30.5 IL1B CCL2 APOL1 ALB
20 human immunodeficiency virus infectious disease 30.5 TNF TLR9 IL4 IL10 IFNG IDO1
21 sleep disorder 30.5 TNF IL6 IL1B IL10 CXCL8 ALB
22 myositis 30.5 TNF IL6 IL1B IL1A IFNG CXCL8
23 mucocutaneous leishmaniasis 30.5 TNF TLR9 IL4 IL10 IFNG
24 endomyocardial fibrosis 30.4 TNF IL4 IL10
25 visceral leishmaniasis 30.4 TNF TLR9 IL4 IL1B IL18 IL10
26 choroiditis 30.4 TNF IL10 IFNG
27 tetanus 30.4 TNF IL6 IL4 IL1B IL1A IL10
28 myelitis 30.3 TNF IL6 IL10 CXCL8
29 liver disease 30.3 TNF IL6 IL1B IL1A CXCL8 ALB
30 alopecia 30.3 TNF IL4 IL1B IFNG
31 transverse myelitis 30.3 TNF IL6 IL10 CXCL8
32 iridocyclitis 30.3 TNF IL6 IL1B IL10
33 orchitis 30.3 TNF IL6 IL1B IL10
34 brucellosis 30.3 TNF IL6 IL4 IL18 IL10 IFNG
35 spotted fever 30.3 TNF IL10 IFNG IDO1 CXCL10
36 chorioretinitis 30.2 TNF IL6 IL1B IL10 IFNG
37 hypereosinophilic syndrome 30.2 IL4 IL10 IFNG CXCL8
38 brain edema 30.2 IL6 IL1B IFNG ALB
39 lymphocytic choriomeningitis 30.2 MYD88 IL6 CXCL8
40 trichomoniasis 30.2 TNF IL6 IL1B IL10 CXCL8
41 cryoglobulinemia 30.2 TNF IL6 IL1B IFNG CXCL10
42 central nervous system disease 30.2 TNF IL6 IL1B IFNG CCL2 ALB
43 pericarditis 30.2 TNF IL6 IL1B IFNG CXCL8
44 polyneuropathy 30.2 TNF IL6 IL1B ALB
45 cutaneous leishmaniasis 30.2 TNF TLR9 IL6 IL4 IL1B IL10
46 diphtheria 30.2 TNF IL4 IL1B IFNG ALB
47 exanthem 30.2 TNF IL6 IL1B IL18 IL10 IFNG
48 cysticercosis 30.2 IL6 IL4 IL1B IL18 IL10
49 purpura 30.2 TNF IL6 IL4 IL1B IL10 IFNG
50 rubella 30.2 TNF IL6 IL4 IL1B IL10 IFNG

Graphical network of the top 20 diseases related to Trypanosomiasis:



Diseases related to Trypanosomiasis
Sources

Symptoms & Phenotypes for Trypanosomiasis

About this section

GenomeRNAi Phenotypes related to Trypanosomiasis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CXCL8 IL10 IL18 IL1A IL1B MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 CXCL8 IL10 IL18 IL1B MYD88 TNF

MGI Mouse Phenotypes related to Trypanosomiasis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 ALB CXCL10 HP IDO1 IFNG IL10
2 cardiovascular system MP:0005385 10.26 ALB CXCL10 HP IDO1 IFNG IL10
3 hematopoietic system MP:0005397 10.22 CXCL10 HP IDO1 IFNG IL10 IL18
4 homeostasis/metabolism MP:0005376 10.21 ALB CXCL10 HP IDO1 IFNG IL10
5 immune system MP:0005387 10.2 ALB CCL2 CXCL10 HP IDO1 IFNG
6 digestive/alimentary MP:0005381 10.09 ALB IFNG IL10 IL18 IL4 IL6
7 mortality/aging MP:0010768 10 ALB AMD1 CXCL10 HP IFNG IL10
8 liver/biliary system MP:0005370 9.86 ALB HP IFNG IL10 IL4 IL6
9 neoplasm MP:0002006 9.61 ALB HP IFNG IL10 IL1A IL1B
10 renal/urinary system MP:0005367 9.23 ALB HP IDO1 IFNG IL4 IL6
Sources

Drugs & Therapeutics for Trypanosomiasis

About this section

Drugs for Trypanosomiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nifurtimox Approved, Investigational Phase 2, Phase 3 23256-30-6
2
Ornithine Approved, Nutraceutical Phase 2, Phase 3 70-26-8, 3184-13-2 6262
3 Melarsoprol Investigational Phase 3 494-79-1
4 Immunologic Factors Phase 3
5 Immunosuppressive Agents Phase 3
6 Benzonidazole Phase 3
7 polysaccharide-K Phase 2, Phase 3
8 Anti-Infective Agents Phase 2, Phase 3
9 Antiprotozoal Agents Phase 2, Phase 3
10 Antiparasitic Agents Phase 2, Phase 3
11
Pentamidine Approved, Investigational Phase 2 100-33-4 4735
12
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
13
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
14
Maleic acid Experimental Phase 2 110-16-7 444266
15
Pafuramidine Investigational Phase 2 186953-56-0
16 Antifungal Agents Phase 2
17 Immunoglobulin G
18 Immunoglobulin M
19 Immunoglobulins, Intravenous
20 Immunoglobulins
21 Antibodies

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Stage Completed NCT00906880 Phase 4 Nifurtimox-Eflronithine Combination Treatment (NECT)
2 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
3 Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study Completed NCT02169557 Phase 2, Phase 3 Fexinidazole
4 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
5 Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study Completed NCT02184689 Phase 2, Phase 3 fexinidazole
6 Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study Completed NCT01685827 Phase 2, Phase 3 Fexinidazole;Nifurtimox;Eflornithine
7 Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial Completed NCT00123916 Phase 3 Benznidazole;Placebo
8 Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial Recruiting NCT03974178 Phase 2, Phase 3 Fexinidazole
9 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring Recruiting NCT04099628 Phase 2, Phase 3
10 Efficacy and Safety Study of Acoziborole (SCYX-7158) in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study Active, not recruiting NCT03087955 Phase 2, Phase 3 Acoziborole (SCYX-7158)
11 An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage Active, not recruiting NCT03025789 Phase 3 Fexinidazole
12 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
13 Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda Terminated NCT00489658 Phase 2, Phase 3 Eflornithine plus Nifurtimox combination therapy
14 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
15 Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00802594 Phase 2 DB289
16 Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis Completed NCT00803933 Phase 2 DB289;Pentamidine
17 A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition Completed NCT02571062 Phase 1 Fexinidazole
18 Randomized, Double-blind, Placebo-controlled Sequential Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCYX-7158 After Single Oral Ascending Doses in Healthy Male Volunteers Completed NCT01533961 Phase 1 SCYX-7158;Placebo
19 Randomized, Double-blind, Placebo-controlled Study of the Tolerability, and Pharmacokinetics of Fexinidazole After Single and Repeated Oral Ascending Doses, Completed by a Comparative Bioavailability Study of an Oral Suspension Versus a Tablet and an Exploratory Assessment of Food Effect, in Healthy Male Volunteers Completed NCT00982904 Phase 1 Fexinidazole/Placebo
20 An Open Label, Single-dose, Single Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-Acoziborole Recruiting NCT04270981 Phase 1 [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
21 Double-blind, Placebo Controlled, Randomized Multiple Ascending Dose Study in Fed Conditions for Ten Days Dosing Regimen With a Loading Dose to Evaluate the Safety, the Tolerability and the Pharmacokinetics of Oral Fexinidazole in 36 Healthy Male Sub-Saharan Volunteers. Terminated NCT01483170 Phase 1 Tablets Fexinidazole;Placebo
22 Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria Unknown status NCT03394976
23 Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan Completed NCT01766830
24 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure Active, not recruiting NCT03112655
25 Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection Active, not recruiting NCT03356665

Search NIH Clinical Center for Trypanosomiasis

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: trypanosomiasis

Sources

Genetic Tests for Trypanosomiasis

About this section
Sources

Anatomical Context for Trypanosomiasis

About this section

MalaCards organs/tissues related to Trypanosomiasis:

40
Brain, Heart, T Cells, Kidney, Spleen, Bone Marrow, Eye
Sources

Publications for Trypanosomiasis

About this section

Articles related to Trypanosomiasis:

(show top 50) (show all 5558)
# Title Authors PMID Year
1
The prolyl oligopeptidase family. 61 54
11915948 2002
2
Chagas Disease: Chronic Chagas Cardiomyopathy. 61
31983471 2021
3
Anti-leishmanial and anti-trypanosomal natural products from endophytes. 61
33409640 2021
4
Antiprotozoal QSAR modelling for trypanosomiasis (Chagas disease) based on thiosemicarbazone and thiazole derivatives. 61
33333422 2021
5
Physiological and proteomic profiles of Trypanosoma brucei rhodesiense parasite isolated from suramin responsive and non-responsive HAT patients in Busoga, Uganda. 61
33588295 2021
6
New Pd-Fe ferrocenyl antiparasitic compounds with bioactive 8-hydroxyquinoline ligands: a comparative study with their Pt-Fe analogues. 61
33449983 2021
7
Antitrypanosomal and Antileishmanial Activity of Chalcones and Flavanones from Polygonum salicifolium. 61
33562567 2021
8
Tryp-ing up metabolism: role of metabolic adaptations in kinetoplastid disease pathogenesis. 61
33526564 2021
9
Modulation of trypanosome establishment in Glossina palpalis palpalis by its microbiome in the Campo sleeping sickness focus, Cameroon. 61
33571685 2021
10
Accelerating elimination of sleeping sickness from the Guinean littoral through enhanced screening in the post-Ebola context: A retrospective analysis. 61
33591980 2021
11
Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice. 61
33594070 2021
12
Update on relevant trypanosome peptidases: Validated targets and future challenges. 61
33271348 2021
13
Potential impacts of climate change on geographical distribution of three primary vectors of African Trypanosomiasis in Tanzania Maasai Steppe; G. m. morsitans, G. pallidipes and G. swynnertoni. 61
33571190 2021
14
A case of Trypanosoma evansi in a German Shepherd dog in Vietnam. 61
32931934 2021
15
Genetic Diversity of African Trypanosomes in Tsetse Flies and Cattle From the Kafue Ecosystem. 61
33585616 2021
16
Singly and doubly modified analogues of C20-epi-salinomycin: A new group of antiparasitic agents against Trypanosoma brucei. 61
33071053 2021
17
Reliable, scalable functional genetics in bloodstream-form Trypanosoma congolense in vitro and in vivo. 61
33481935 2021
18
Tsetse blood-meal sources, endosymbionts and trypanosome-associations in the Maasai Mara National Reserve, a wildlife-human-livestock interface. 61
33406097 2021
19
Structure of trypanosome coat protein VSGsur and function in suramin resistance. 61
33462435 2021
20
Repurposing the orphan drug nitisinone to control the transmission of African trypanosomiasis. 61
33497373 2021
21
Medicine donation programmes supporting the global drive to end the burden of neglected tropical diseases. 61
33452881 2021
22
Harnessing technology and portability to conduct molecular epidemiology of endemic pathogens in resource-limited settings. 61
32945867 2021
23
Effect of zebra skin-derived compounds on field catches of the human African trypanosomiasis vector Glossina fuscipes fuscipes. 61
33160957 2021
24
An atlas of tsetse and animal African trypanosomiasis in Zimbabwe. 61
33446276 2021
25
Potentials of marine natural products against malaria, leishmaniasis, and trypanosomiasis parasites: a review of recent articles. 61
33482912 2021
26
Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. 61
33513134 2021
27
Basic Biology of Trypanosoma brucei with reference to the development of chemotherapies. 61
33463458 2021
28
The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines. 61
33070078 2021
29
Bioactivity of fractions and constituents of Piper capense fruits towards a broad panel of cancer cells. 61
33529639 2021
30
Computational Identification of Master Regulators Influencing Trypanotolerance in Cattle. 61
33429951 2021
31
The influence of vector-borne disease on human history: socio-ecological mechanisms. 61
33501751 2021
32
Mice immunization with Trypanosoma brucei gambiense translationally controlled tumor protein modulates immunoglobulin and cytokine production, as well as parasitaemia and mice survival after challenge with the parasite. 61
33217546 2021
33
Environmental neurology in the tropics. 61
33445007 2020
34
Recent Advancement in the Search of Innovative Antiprotozoal Agents Targeting Trypanothione Metabolism. 61
32805075 2020
35
Halogenated tryptophan derivatives disrupt essential transamination mechanisms in bloodstream form Trypanosoma brucei. 61
33275612 2020
36
Isolation and Antitrypanosomal Characterization of Furoquinoline and Oxylipin from Zanthoxylum zanthoxyloides. 61
33322191 2020
37
Antischistosomal, antionchocercal and antitrypanosomal potentials of some Ghanaian traditional medicines and their constituents. 61
33382717 2020
38
Seropositivity for Trypanosoma cruzi and Leishmania mexicana in dogs from a metropolitan region of Central Mexico. 61
33308745 2020
39
Repurposing bioenergetic modulators against protozoan parasites responsible for tropical diseases. 61
32829099 2020
40
Improved Access to Diagnostics for Rhodesian Sleeping Sickness around a Conservation Area in Malawi Results in Earlier Detection of Cases and Reduced Mortality. 61
32959623 2020
41
Case Report: COVID-19 and Chagas Disease in Two Coinfected Patients. 61
33025877 2020
42
Sleeping hearts: 12 years after a follow up study on cardiac findings due to sleeping sickness. 61
33392376 2020
43
Population Structure and Migration Patterns of the Tsetse Fly Glossina fuscipes in Congo-Brazzaville. 61
33372648 2020
44
Human African trypanosomiasis & heart. 61
32967478 2020
45
The Actigraphy Sleep Score: A New Biomarker for Diagnosis, Disease Staging, and Monitoring in Human African Trypanosomiasis. 61
33078699 2020
46
Cost of a new method of active screening for human African trypanosomiasis in the Democratic Republic of the Congo. 61
33315896 2020
47
Analytical sensitivity of loopamp and quantitative real-time PCR on dried blood spots and their potential role in monitoring human African trypanosomiasis elimination. 61
33011238 2020
48
Parasitological and clinical-pathological findings in twelve outbreaks of acute trypanosomiasis in dairy cattle in Rio de Janeiro state, Brazil. 61
33308723 2020
49
American trypanosomiasis (Chagas disease) in solid organ transplantation. 61
32738158 2020
50
Parasitological and molecular detection of Trypanosoma spp. in cattle, goats and sheep in Somalia. 61
32951618 2020
Sources

Variations for Trypanosomiasis

About this section
Sources

Expression for Trypanosomiasis

About this section
Search GEO for disease gene expression data for Trypanosomiasis.
Sources

Pathways for Trypanosomiasis

About this section

Pathways related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.16 TNF TLR9 MYD88 IL6 IL4 IL1B
2
ERK Signaling 63
Show member pathways
 13.92 TNF IL6 IL4 IL1B IL1A IL18
3
Viral mRNA Translation 65
Show member pathways
 13.91 TNF ODC1 MYD88 IL6 IL1B IDO1
4
PEDF Induced Signaling 63
Show member pathways
 13.81 TNF IL6 IL4 IL1B IL1A IL18
5
TGF-Beta Pathway 63
Show member pathways
 13.66 TNF IL6 IL4 IL1B IL1A IL18
6
Akt Signaling 63
Show member pathways
 13.56 TNF TLR9 MYD88 IL6 IL4 IL1B
7
Cytokine Signaling in Immune system 65
Show member pathways
 13.51 TNF MYD88 IL6 IL4 IL1B IL1A
8
PAK Pathway 63
Show member pathways
 13.46 TNF IL6 IL4 IL1B IL1A IL18
9
IL-2 Pathway 63
Show member pathways
 13.31 TNF TLR9 MYD88 IL4 IL1B IL1A
10
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.23 TNF TLR9 MYD88 IL6 IL1B IL10
11
Human cytomegalovirus infection 36
Show member pathways
 13.04 TNF MYD88 IL6 IL1B CXCL8 CCL2
12
Allograft rejection 36 1
Show member pathways
 13.03 TNF IL6 IL4 IL1B IL1A IL10
13
Herpes simplex virus 1 infection 36
12.96 TNF TLR9 MYD88 IL6 IL1B IFNG
14
Measles 36
Show member pathways
 12.95 TNF TLR9 MYD88 IL6 IL1B IL1A
15
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.92 TNF TLR9 MYD88 IL6 IL1B IL1A
16
Salmonella infection (KEGG) 36
Show member pathways
 12.91 TNF TLR9 MYD88 IL6 IL1B IL18
17
NF-KappaB Family Pathway 63
Show member pathways
 12.83 TNF TLR9 MYD88 IL6 IL1B IL1A
18
Th17 cell differentiation 36
Show member pathways
 12.79 TNF IL6 IL4 IL1B IL1A IL18
19
Immune response IL-23 signaling pathway 23
Show member pathways
 12.77 TNF IL6 IL1B IL18 IL10 IFNG
20
T cell receptor signaling pathway 36
Show member pathways
 12.76 TNF TLR9 MYD88 IL6 IL4 IL1B
21
Immune response NFAT in immune response 23
Show member pathways
 12.73 TNF IL4 IL18 IL10 IFNG
22
TRAF Pathway 63
Show member pathways
 12.69 TNF TLR9 MYD88 IL1B IL1A
23
NF-kappaB Signaling 4
12.69 TNF TLR9 MYD88 IL4 IL1B IL10
24
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.66 MYD88 IL6 IL1B IL18 CXCL10
25
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.65 TNF MYD88 IFNG CXCL8 CXCL10
26
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.55 TNF IL6 IL18 IL10 CXCL8 CXCL10
27
Folate Metabolism 1
Show member pathways
 12.54 TNF IL6 IL4 IL1B IFNG CCL2
28
Shigellosis 36
12.53 TNF MYD88 IL1B IL18 CXCL8
29
Toll Comparative Pathway 63
Show member pathways
 12.52 TNF MYD88 IL6 IL1B IL1A IFNG
30
IL-17 Family Signaling Pathways 64
Show member pathways
 12.51 TNF IL6 IL4 IL1B IFNG CXCL8
31
Toxoplasmosis 36
Show member pathways
 12.47 TNF MYD88 IL4 IL1B IL1A IL10
32
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.46 TNF TLR9 MYD88 IL6 IL1A CXCL8
33
NOD-like receptor signaling pathway 36
12.44 TNF MYD88 IL6 IL1B IL18 CXCL8
34
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.42 TNF IL6 IL4 IL1B IL1A IL18
35
C-type lectin receptor signaling pathway 36
Show member pathways
 12.41 TNF TLR9 MYD88 IL6 IL1B IL10
36
IL-1 signaling pathway 1
Show member pathways
 12.38 MYD88 IL1B IL1A CCL2
37
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.37 TNF IL6 IL1B IL1A IL10 CXCL8
38
Tuberculosis 36
12.37 TNF TLR9 MYD88 IL6 IL1B IL1A
39
Necroptosis 36
Show member pathways
 12.3 TNF IL1B IL1A IFNG
40
Colorectal Cancer Metastasis 63
12.28 TNF TLR9 IL6 IFNG
41
Bacterial infections in CF airways 23
Show member pathways
 12.27 TNF TLR9 MYD88 IL6 IL4 IL1B
42
Fluid shear stress and atherosclerosis 36
12.26 TNF IL1B IL1A IFNG CCL2
43
Yersinia infection 36
12.25 TNF MYD88 IL6 IL1B IL18 IL10
44
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.18 TNF IL6 IL4 IL10 IFNG
45
Osteoclast differentiation 36
12.16 TNF IL1B IL1A IFNG
46
TNF signaling pathway 36
12.16 TNF IL6 IL1B CXCL10 CCL2
47
Amoebiasis 36
12.15 TNF IL6 IL1B IL10 IFNG CXCL8
48
AGE-RAGE signaling pathway in diabetic complications 36
12.14 TNF IL6 IL1B IL1A CXCL8 CCL2
49
Senescence and Autophagy in Cancer 1
12.13 IL6 IL1B IL1A IFNG CXCL8
50
IL12-mediated signaling events 1
Show member pathways
 12.1 IL4 IL1B IL18 IFNG
Sources

GO Terms for Trypanosomiasis

About this section

Cellular components related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNF TLR9 IL6 IL4 IL1B IL1A
2 extracellular space GO:0005615 9.5 TNF IL6 IL4 IL1B IL1A IL18
3 blood microparticle GO:0072562 9.46 HPR HP APOL1 ALB

Biological processes related to Trypanosomiasis according to GeneCards Suite gene sharing:

(show top 50) (show all 82)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 TLR9 MYD88 IL6 IL4 IL1B IL18
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF TLR9 IL6 IL4 IL1A IL18
3 negative regulation of cell proliferation GO:0008285 10.15 IL6 IL1B IL1A IL10 CXCL8
4 defense response to bacterium GO:0042742 10.09 TNF TLR9 MYD88 IL10 HP
5 positive regulation of gene expression GO:0010628 10.07 TNF TLR9 MYD88 IL6 IL4 IL1B
6 defense response to virus GO:0051607 10.05 TLR9 IL6 IFNG CXCL10
7 receptor-mediated endocytosis GO:0006898 10.04 HPR HP APOL1 ALB
8 response to lipopolysaccharide GO:0032496 10.03 MYD88 IL1B IL10 IDO1 CXCL10
9 defense response GO:0006952 10.02 TNF HP CXCL8 CXCL10
10 positive regulation of DNA-binding transcription factor activity GO:0051091 10 TNF IL6 IL1B IL10
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR9 MYD88 IL6 IL1B IL18
12 positive regulation of JNK cascade GO:0046330 9.97 TNF TLR9 MYD88 IL1B
13 response to virus GO:0009615 9.97 TNF ODC1 MYD88 IFNG CXCL10
14 regulation of insulin secretion GO:0050796 9.96 TNF IL6 IL1B IFNG
15 positive regulation of inflammatory response GO:0050729 9.96 TNF TLR9 IL1B IL18 IFNG
16 cellular response to organic cyclic compound GO:0071407 9.94 TNF IL1B IL18 CCL2
17 neutrophil chemotaxis GO:0030593 9.93 CXCL8 CXCL10 CCL2
18 negative regulation of interleukin-6 production GO:0032715 9.93 TNF TLR9 IL10
19 chemokine-mediated signaling pathway GO:0070098 9.93 CXCL8 CXCL10 CCL2
20 response to glucocorticoid GO:0051384 9.93 TNF IL6 IL10
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.93 TNF TLR9 IL1B IL18
22 positive regulation of tumor necrosis factor production GO:0032760 9.93 TLR9 MYD88 IL6 IL1A IFNG
23 positive regulation of T cell proliferation GO:0042102 9.92 IL6 IL4 IL1B
24 positive regulation of interleukin-1 beta production GO:0032731 9.92 TNF IL6 IFNG
25 positive regulation of interferon-gamma production GO:0032729 9.92 TNF TLR9 IL1B IL18
26 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 IL4 IL18 IFNG
27 positive regulation of smooth muscle cell proliferation GO:0048661 9.91 TNF MYD88 IL6 IL18
28 humoral immune response GO:0006959 9.91 TNF IL6 IFNG CCL2
29 cellular response to lipopolysaccharide GO:0071222 9.91 TNF MYD88 IL6 IL1B IL1A IL10
30 positive regulation of phagocytosis GO:0050766 9.9 TNF IL1B IFNG
31 positive regulation of nitric oxide biosynthetic process GO:0045429 9.9 TNF IL1B IFNG
32 positive regulation of cytokine production GO:0001819 9.9 TNF IL1A IL10 IFNG
33 inflammatory response GO:0006954 9.9 TNF TLR9 MYD88 IL6 IL1B IL1A
34 positive regulation of interleukin-12 production GO:0032735 9.89 TLR9 IFNG IDO1
35 protein kinase B signaling GO:0043491 9.89 TNF IL1B CCL2
36 positive regulation of interleukin-10 production GO:0032733 9.89 TLR9 IL6 IL4
37 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.89 TNF IL1B IL1A
38 positive regulation of JAK-STAT cascade GO:0046427 9.88 TNF IL6 IL10
39 microglial cell activation GO:0001774 9.88 TNF IL4 IFNG
40 positive regulation of interleukin-8 production GO:0032757 9.88 TNF TLR9 MYD88 IL6 IL1B
41 positive regulation of vascular endothelial growth factor production GO:0010575 9.87 IL6 IL1B IL1A
42 positive regulation of interleukin-6 production GO:0032755 9.87 TNF TLR9 MYD88 IL6 IL1B IL1A
43 negative regulation of neurogenesis GO:0050768 9.86 TNF IL6 IL1B
44 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.85 TNF MYD88 IL6
45 negative regulation of myoblast differentiation GO:0045662 9.85 TNF IL18 CXCL10
46 positive regulation of immunoglobulin production GO:0002639 9.84 TLR9 IL6 IL10
47 positive regulation of glial cell proliferation GO:0060252 9.84 TNF IL6 IL1B
48 positive regulation of interleukin-17 production GO:0032740 9.83 MYD88 IL6 IL18
49 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.83 TLR9 IFNG CCL2
50 positive regulation of chemokine production GO:0032722 9.83 TNF TLR9 MYD88 IL6 IFNG

Molecular functions related to Trypanosomiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CXCL8 CXCL10 CCL2
2 cytokine activity GO:0005125 9.36 TNF IL6 IL4 IL1B IL1A IL18
3 interleukin-1 receptor binding GO:0005149 9.26 TLR9 MYD88 IL1B IL1A
4 hemoglobin binding GO:0030492 9.16 HPR HP
Sources

Sources for Trypanosomiasis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....